BD&L Strategy, Business Development & Licensing, Rare Disease, Cell Therapy, AI in Drug Discovery, Biotech Investing, Therapeutic Area Strategy, Portfolio Analysis

Analytical Teardowns

The cost of chasing validated science: how Pfizer overpays when it needs certainty

Pfizer has spent $88 billion on external innovation since 2018. Majority of that capital sits in just four deals and 37% in one. Jump into the dissection of the dealmaker narrative to find out if this theory holds true for Pfizer.

AstraZeneca, Pharma Strategy, Open Innovation, M&A / Mergers and Acquisitions, Corporate Venture Capital (CVC), Oncology, Cardiometabolic Disease

Will AstraZeneca's open innovation engine turn it into the next most valuable pharma company?

AstraZeneca's Open Innovation doctrine has already delivered a big chunk of its 16 Blockbusters and there are many assets lined up to become the next big ones. Jump in to see if the money is going where it should.